巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Ultragenyx Pharmaceutical

RARE
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Ultragenyx Pharmaceutical - 延遲價格・最後更新於 14/01 12:14
最高位
72.080
最低位
68.270
開市價
--
前收市價
69.890
成交量(千)
23.82
成交額(百萬)
14.87
買入
--
賣出
--
每手股數
--
市值(百萬)
4,907.68
市盈率
--
息率
--
差價
--
52週高低
175.000 - 68.200
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Ultragenyx Pharmaceutical
證券代碼
RARE.US
所屬板塊
Biotechnology
公司業務
Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
發行量
66949244
公司總部
60 Leveroni Court
公司網址
https://www.ultragenyx.com
公司電郵
dkeatley@ultragenyx.com
公司電話
+1 415 483-8800
暫無內容

關於

Ultragenyx Pharmaceutical(RARE.US)所屬的行業板塊為Biotechnology。
Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
詳細公司背景可參考: https://www.ultragenyx.com